Drug intelligence / Profile preview

Qingyi No. 1 granule

Development stage: Unknown
Lead developer: Longhua Hospital Shanghai University of Traditional Chinese Medicine
Administration: Oral

Overview

Qingyi No. 1 granule is a traditional Chinese medicine (TCM) formulation developed by Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. It is specifically designed for the treatment of epidemic hemorrhagic fever (also known as hemorrhagic fever with renal syndrome, HFRS) during the fever period. The granule is used as an adjunctive therapy alongside standard Western medical treatments to prevent the progression of the disease to more critical stages. As a TCM product, it likely consists of a specific blend of herbal extracts aimed at clearing heat and detoxifying, though the exact herbal composition is not detailed in the provided context.

Other names: Qingyi No. 1

Beyond the preview

Go deeper on Qingyi No. 1 granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qingyi No. 1 granule.

Explore the full profile